Need help or have questions about your order? Call 510-991-8265Questions about your order? Call 510-991-8265

Sign InShop GLPs
Shop GLPs

GHK-Cu Dosing in Renal Impairment: What Clinicians and Patients Need to Know

By
Published Updated Last reviewed
10 linked public sourcesEditorial, sourcing, and corrections policy

At a glance

  • FDA-approved GHK-Cu drug / None known; topical copper peptides are sold as cosmetics [5]
  • Established GHK-Cu dose / None [2]
  • Copper elimination / Mainly bile; also through the kidneys [3]
  • Serum copper in CKD / Higher stage linked to higher copper in 194 patients [4]
  • Injectable GHK-Cu / Nominated but withdrawn, with an FDA immunogenicity concern [6]
  • Normal serum copper (cupric chloride label) / 80 to 163 mcg/dL [3]

Is there a GHK-Cu dose to adjust for kidney function?

No. No FDA-approved drug is known to contain GHK-Cu, and no FDA-approved GHK-Cu dose or kidney-adjusted dose has been established [1][2]. Non-injectable GHK-Cu is in category 1 of FDA's interim compounding policy, the group under evaluation for the bulks list, and FDA has said it intends to consult its Pharmacy Compounding Advisory Committee on it before the end of February 2027 [1][7]. Compounded drugs are not reviewed by FDA for safety, effectiveness or quality before marketing [8].

Injectable GHK-Cu sits in a nominated-but-withdrawn table; FDA states that compounded injectable drugs containing GHK-Cu may pose a risk for immunogenicity due to the potential for aggregation and peptide-related impurities, with limited human data to inform safety [6].

The venous-ulcer trial tested a topical cream and the laser-resurfacing trial tested skin-care products containing GHK-Cu [2][9]. The only drug-style human trial found used a 0.4% tripeptide copper complex cream in venous ulcers, and it was no different from an inert vehicle for ulcer size [2]. A 2026 systematic review of 64 retained records described the human literature as thin and fragmented, with most randomized trials small and run on facial cosmetic creams [10].

What is documented about copper and the kidneys?

Cupric chloride injection is a different product from GHK-Cu [3]. Its label states that copper is primarily excreted through the bile into the gastrointestinal tract and is also eliminated through the kidneys, and gives normal serum copper values of 80 to 163 mcg/dL, mean about 110 mcg/dL [3].

In a study of 194 people with CKD stages 1, 2, 3a, 3b and 4, higher stage was associated with higher serum copper (Ptrend = 0.004) and lower zinc after adjustment for age, sex, smoking, education, diabetes, hypertension and BMI [4]. That study measured elements in blood; it gave nobody a copper product [4].

Topical products

HealthRX.com offers a copper peptide cream. The trials above do not establish a kidney-adjusted dose for any GHK-Cu product.

Frequently asked questions

Is there a GHK-Cu dose adjustment for kidney disease?
No. No FDA-approved drug is known to contain GHK-Cu, so there is no dose to adjust [1][2].
Does kidney disease raise copper levels?
In a study of 194 people with CKD stages 1 to 4, higher stage was associated with higher serum copper (Ptrend = 0.004) and lower zinc [4]. That study measured blood elements only and did not test any copper product.
Does the cupric chloride label apply to GHK-Cu?
No. That label covers cupric chloride, a different product. It states that copper is mainly excreted in bile and also eliminated through the kidneys, and it warns that copper given to a patient with Wilson disease may cause increased hepatic accumulation and aggravation of hepatocellular degeneration [3].

References

  1. U.S. Food and Drug Administration. U.S. Food and Drug Administration
  2. Bishop JB, Phillips LG, Mustoe TA, VanderZee AJ, Wiersema L, Roach DE, et al. A prospective randomized evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcers. J Vasc Surg. 1992;16(2):251-7. A prospective randomized evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcers
  3. U.S. National Library of Medicine, DailyMed. COPPER (cupric chloride) prescribing information. COPPER (cupric chloride) label
  4. Kung WJ, Shih CT, Lee CH, Lin CC. The Divalent Elements Changes in Early Stages of Chronic Kidney Disease. Biol Trace Elem Res. 2018;185(1):30-35. The Divalent Elements Changes in Early Stages of Chronic Kidney Disease
  5. Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?) | FDA. Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?) | FDA
  6. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA
  7. Bulk Drug Substances Used in Compounding of the FD&C Act | FDA. Bulk Drug Substances Used in Compounding of the FD&C Act | FDA
  8. Official web page. Official web page
  9. Miller TR, Wagner JD, Baack BR, Eisbach KJ. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg. 2006;8(4):252-9. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin
  10. Najafi N, Maatouk H, Vardanyan KG, Vartanian KB, Agrawal DK. A Systematic Review of the Mechanisms and Therapeutic Applications of GHK-Cu (Glycyl-L-Histidyl-L-Lysine-Copper Complex) in Topical Microneedle Delivery: A Case for Expanded Clinical Trials. Arch Intern Med Res. 2026;9(3):269-293. A Systematic Review of the Mechanisms and Therapeutic Applications of GHK-Cu (Glycyl-L-Histidyl-L-Lysine-Copper Complex) in Topical Microneedle Delivery: A Case for Expanded Clinical Trials
Evidence overview for GHK-Cu Dosing in Renal Impairment: What Clinicians and Patients Need to Know